- Home
- SGML vs VIR Comparison
SGML vs VIR Comparison
Compare SGML & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- VIR
- Stock Information
- Founded
- SGML 2011
- VIR 2016
- Country
- SGML Brazil
- VIR United States
- Employees
- SGML N/A
- VIR N/A
- Industry
- SGML Industrial Machinery/Components
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- VIR Health Care
- Exchange
- SGML Nasdaq
- VIR Nasdaq
- Market Cap
- SGML 1.2B
- VIR 1.4B
- IPO Year
- SGML N/A
- VIR 2019
- Fundamental
- Price
- SGML $11.39
- VIR $9.70
- Analyst Decision
- SGML Strong Buy
- VIR Buy
- Analyst Count
- SGML 2
- VIR 6
- Target Price
- SGML $18.00
- VIR $34.83
- AVG Volume (30 Days)
- SGML 485.3K
- VIR 3.8M
- Earning Date
- SGML 03-31-2025
- VIR 02-20-2025
- Dividend Yield
- SGML N/A
- VIR N/A
- EPS Growth
- SGML N/A
- VIR N/A
- EPS
- SGML N/A
- VIR N/A
- Revenue
- SGML $142,748,436.00
- VIR $78,618,000.00
- Revenue This Year
- SGML $30.28
- VIR N/A
- Revenue Next Year
- SGML $56.58
- VIR N/A
- P/E Ratio
- SGML N/A
- VIR N/A
- Revenue Growth
- SGML 48.43
- VIR N/A
- 52 Week Low
- SGML $8.47
- VIR $6.56
- 52 Week High
- SGML $19.20
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- SGML 32.82
- VIR 52.17
- Support Level
- SGML $10.57
- VIR $10.09
- Resistance Level
- SGML $11.17
- VIR $11.39
- Average True Range (ATR)
- SGML 0.50
- VIR 0.71
- MACD
- SGML -0.10
- VIR -0.11
- Stochastic Oscillator
- SGML 8.43
- VIR 16.57
About SGML Sigma Lithium Corporation
Sigma Lithium Corp is dedicated to powering the next generation of electric vehicle batteries with environmentally sustainable and high-purity lithium. The company is in construction at its wholly owned Grota do Cirilo Project in Brazil, one of the highest-grade hard rock lithium spodumene deposits in the Americas.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.